Q. Bisantrene is not new. How can RAC monetise if it is out of patent?, page-81

Daniel, thanks and appreciated. I “get it” the conventional wisdom. However, each marvelous milestone and announcement isn’t generating the heightened level of interest and investor logic which usually attracts bigger chunks of investment.
I can see from my likes above I am not on the side of the majority BUT there is a missing link. The previous posters here today have hinted at or tried to unearth the cause.
i am a welded on investor so my thoughts are merely meant to create unconventional thinking. “It’s Biotech” seems to be the common and accepted response but we collectively should shift the paradigm IMHO. Hoping the roadshow can.